Cell therapy (CAR-T) · Kills target cells, directed at GPRC5D · developed by BRISTOL MYERS SQUIBB
Arlocabtagene autoleucel is an autologous T-lymphocyte cell therapy engineered to express a chimeric antigen receptor specific for GPRC5D, a protein overexpressed in certain malignancies such as multiple myeloma. The engineered cells recognize GPRC5D-expressing tumor cells and induce selective toxicity against them. It is being studied in relapsed or refractory multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06615479 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | BMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed or Refractory Multiple Myeloma (RRMM)
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMY page.
See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMY catalysts and pipeline →